Details of the SBP
General Information of Synthetic Binding Protein (SBP) (ID: SBP003375) | ||||||
---|---|---|---|---|---|---|
SBP Name |
scFv Efungumab
|
|||||
Synonyms |
hsp90 grAB; Mycograb
|
|||||
Molecular Weight | 26.5 kDa | |||||
Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
Highest Status | Phase III | |||||
Sequence Length | 250 | |||||
SBP Sequence |
>scFv Efungumab
MAEVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYI NYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTV SSGGGGSGGGGSGGGGSDVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKA PKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTK VDIKRAAALE |
|||||
3D Structure | ||||||
Computationally Modelled Structure | ||||||
Click to Save PDB File | ||||||
Protein Scaffold Information of This SBP | ||||||
---|---|---|---|---|---|---|
Scaffold ID | PS057 | [1] | ||||
Scaffold Name | scFv | |||||
Scaffold Class | Antibody fragment | |||||
Fold Type | Beta-Sheets + Loops | |||||
Binding Target(s) of This SBP (BTS) |
---|
BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
---|---|---|---|---|---|---|
Heat shock protein HSP 90-beta | Inhibitor | Cryptococcal Meningitis [ICD-11: 1D01.10]; Breast cancer [ICD-11: 2C6Z] | N.A. | University of South Alabama; NeuTec Pharma | [1] | |
Clinical Trial Information of This SBP | ||||||
---|---|---|---|---|---|---|
NCT00217815 | Click to show the Detail | |||||
Indication | Cancer of the Breast | |||||
Phase | Phase I; Phase II | |||||
Title | Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer | |||||
Status | Completed | |||||
Sponsor | NeuTec Pharma | |||||
NCT00324025 | Click to show the Detail | |||||
Indication | Cryptococcal Meningitis | |||||
Phase | Phase II | |||||
Title | Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS | |||||
Status | Terminated | |||||
Sponsor | Novartis Pharmaceuticals | |||||
NCT00847678 | Click to show the Detail | |||||
Indication | Cryptococcal Meningitis | |||||
Phase | Phase II | |||||
Title | Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS | |||||
Status | Terminated | |||||
Sponsor | Novartis Pharmaceuticals | |||||